Fig. 1From: Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patientsSurvival analyses by the Kaplan–Meier method according to HRR gene mutation status in the entire cohort (n = 44). (A) Progression-free survival 2 (PFS2) and (B) PFS2 – PFS1Back to article page